


5 What is claimed is:

1. A stent comprising an effective amount of a JNK Inhibitor.
2. The stent of claim 1 having a coating comprising an effective amount of a JNK Inhibitor.
3. The stent of claim 1 comprising a material having an effective amount of a JNK  
10 Inhibitor incorporated therein.
4. The stent according to claim 1, wherein the JNK Inhibitor has the following formula:



15 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof,

wherein:

A is a direct bond,  $-(CH_2)_a-$ ,  $-(CH_2)_bCH=CH(CH_2)_c-$ , or  $-(CH_2)_bC \equiv C(CH_2)_c-$ ;

R<sub>1</sub> is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently from R<sub>3</sub>;

20 R<sub>2</sub> is -R<sub>3</sub>, -R<sub>4</sub>,  $-(CH_2)_bC(=O)R_5$ ,  $-(CH_2)_bC(=O)OR_5$ ,  $-(CH_2)_bC(=O)NR_5R_6$ ,  
 $-(CH_2)_bC(=O)NR_5(CH_2)_cC(=O)R_6$ ,  $-(CH_2)_bNR_5C(=O)R_6$ ,  $-(CH_2)_bNR_5C(=O)NR_6R_7$ ,  
 $-(CH_2)_bNR_5R_6$ ,  $-(CH_2)_bOR_5$ ,  $-(CH_2)_bSO_dR_5$  or  $-(CH_2)_bSO_2NR_5R_6$ ;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently 0, 1, 2, 3 or 4;


25 d is at each occurrence 0, 1 or 2;

5 R<sub>3</sub> is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, heterocycle, heterocycloalkyl, -C(=O)OR<sub>8</sub>, -OC(=O)R<sub>8</sub>, -C(=O)NR<sub>8</sub>R<sub>9</sub>, -C(=O)NR<sub>8</sub>OR<sub>9</sub>, -SO<sub>2</sub>NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>SO<sub>2</sub>R<sub>9</sub>, -CN, -NO<sub>2</sub>, -NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>OR<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>R<sub>9</sub>, -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, or heterocycle fused to  
10 phenyl;

R<sub>4</sub> is alkyl, aryl, arylalkyl, heterocycle or heterocycloalkyl, each being optionally substituted with one to four substituents independently from R<sub>3</sub>, or R<sub>4</sub> is halogen or hydroxy;

R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently hydrogen,  
15 alkyl, aryl, arylalkyl, heterocycle or heterocycloalkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently from R<sub>3</sub>; and R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocycloalkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and  
20 R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently from R<sub>3</sub>.

5. The stent according to claim 1, wherein the JNK Inhibitor has the following formula:



or a pharmaceutically acceptable salt, solvate or stereoisomer thereof,

wherein:

R<sub>1</sub> is aryl or heteroaryl optionally substituted with one to four substituents independently  
30 from R<sub>7</sub>;

5 R<sub>2</sub> is hydrogen;

R<sub>3</sub> is hydrogen or lower alkyl;

R<sub>4</sub> represents one to four optional substituents, wherein each substituent is the same or different and independently halogen, hydroxy, lower alkyl or lower alkoxy;

R<sub>5</sub> and R<sub>6</sub> are the same or different and independently -R<sub>8</sub>, -(CH<sub>2</sub>)<sub>a</sub>C(=O)R<sub>9</sub>,  
10 -(CH<sub>2</sub>)<sub>a</sub>C(=O)OR<sub>9</sub>, -(CH<sub>2</sub>)<sub>a</sub>C(=O)NR<sub>9</sub>R<sub>10</sub>, -(CH<sub>2</sub>)<sub>a</sub>C(=O)NR<sub>9</sub>(CH<sub>2</sub>)<sub>b</sub>C(=O)R<sub>10</sub>,  
-(CH<sub>2</sub>)<sub>a</sub>NR<sub>9</sub>C(=O)R<sub>10</sub>, (CH<sub>2</sub>)<sub>a</sub>NR<sub>11</sub>C(=O)NR<sub>9</sub>R<sub>10</sub>, -(CH<sub>2</sub>)<sub>a</sub>NR<sub>9</sub>R<sub>10</sub>, -(CH<sub>2</sub>)<sub>a</sub>OR<sub>9</sub>,  
-(CH<sub>2</sub>)<sub>a</sub>SO<sub>c</sub>R<sub>9</sub> or -(CH<sub>2</sub>)<sub>a</sub>SO<sub>2</sub>NR<sub>9</sub>R<sub>10</sub>;

or R<sub>5</sub> and R<sub>6</sub> taken together with the nitrogen atom to which they are attached to form a heterocycle or substituted heterocycle;


15 R<sub>7</sub> is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, arylalkyl, heterocycle, heterocycloalkyl, -C(=O)OR<sub>8</sub>, -OC(=O)R<sub>8</sub>, -C(=O)NR<sub>8</sub>R<sub>9</sub>,  
-C(=O)NR<sub>8</sub>OR<sub>9</sub>, -SO<sub>c</sub>R<sub>8</sub>, -SO<sub>c</sub>NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>SO<sub>c</sub>R<sub>9</sub>, -NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>C(=O)R<sub>9</sub>,  
-NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>OR<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>R<sub>9</sub>, -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, or heterocycle fused to  
20 phenyl;

R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub> and R<sub>11</sub> are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, aryl, arylalkyl, heterocycle or heterocycloalkyl;

or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are attached to form a heterocycle;

25 *a* and *b* are the same or different and at each occurrence independently 0, 1, 2, 3 or 4; and  
*c* is at each occurrence 0, 1 or 2.

6. The stent according to claim 1, wherein the JNK Inhibitor has the following formula:




5

or a pharmaceutically acceptable salt, solvate or stereoisomer thereof,

wherein  $R_0$  is -O-, -S-, -S(O)-, -S(O)<sub>2</sub>-, NH or -CH<sub>2</sub>-;

the compound being (i) unsubstituted, (ii) monosubstituted and having a first substituent, or (iii) disubstituted and having a first substituent and a second substituent;

- 10 the first or second substituent, when present, is at the 3, 4, 5, 7, 8, 9, or 10 position,  
 wherein the first and second substituent, when present, are independently alkyl, hydroxy,  
 halogen, nitro, trifluoromethyl, sulfonyl, carboxyl, alkoxycarbonyl, alkoxy, aryl, aryloxy,  
 arylalkyloxy, arylalkyl, cycloalkylalkyloxy, cycloalkyloxy, alkoxyalkyl, alkoxyalkoxy,  
 aminoalkoxy, mono-alkylaminoalkoxy, di-alkylaminoalkoxy, or a group represented by  
 15 formula (a), (b), (c), (d), (e), or (f):



- 5 wherein R<sub>3</sub> and R<sub>4</sub> are taken together and represent alkylidene or a heteroatom-containing cyclic alkylidene or R<sub>3</sub> and R<sub>4</sub> are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl; and
- R<sub>5</sub> is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, 10 alkoxycarbonylalkyl, amino, mono-alkylamino, di-alkylamino, arylamino, arylalkylamino, cycloalkylamino, cycloalkylalkylamino, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl.
7. The stent according to claim 2 wherein the coating comprises a pharmaceutically acceptable carrier.
- 15 8. The stent according to claim 1 wherein the stent is a stent graft.
9. The stent according to claim 1 wherein the stent comprises a polymer.
10. The stent according to claim 9 in which the polymer is a polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, a polymethylmethacrylate, a polyethylene, a poly(ethylene 20 terephthalate), a polyalkylene oxalate, a polyurethane, a polysiloxane, a poly(dimethyl siloxane), a polycyanoacrylate, a polyphosphazene, a poly(amino acid), a ethylene glycol

- 5 I dimethacrylate, a poly(methyl methacrylate), a poly(2-hydroxyethyl methacrylate), a poly(HEMA), or a polyhydroxyalkanoate compound.
11. The stent according to claim 2 wherein the coating is a controlled-release coating.
12. A method for making the stent of claim 2, comprising the step of coating a stent with an effective amount of a JNK Inhibitor.
- 10 13. The method according to claim 12 wherein the stent is a stent graft.
14. The stent according to claim 3 wherein the material having an effective amount of a JNK Inhibitor incorporated therein allows for controlled-release of the JNK Inhibitor.
15. A method for making the stent of claim 3, comprising manufacturing a stent with  
15 material having an effective amount of a JNK Inhibitor incorporated therein.
16. A method for treating or preventing a cardiovascular or renal disease in a patient, comprising implanting the stent of claim 1 into a patient in need thereof.
17. A method for treating or preventing atherosclerosis in a patient, comprising implanting the stent of claim 1 into a patient in need thereof.
- 20 18. The method of claim 16 further comprising surgical intervention.
19. The method of claim 17 further comprising surgical intervention.
20. The method of claim 18 wherein the surgical intervention involves percutaneous coronary intervention, revascularization, percutaneous transluminal coronary angioplasty, carotid percutaneous transluminal angioplasty coronary by-pass grafting or  
25 coronary angioplasty with stent implantation.
21. The method of claim 18 wherein the surgical intervention involves renal angioplasty; peripheral percutaneous transluminal intervention of the iliac, femoral or popliteal arteries; or surgical intervention using impregnated artificial grafts.

- 5     22.     The method of claim 16 wherein the stent is a stent graft.
23.     The method of claim 17 wherein the stent is a stent graft.
24.     The method of claim 20 wherein the implanting occurs prior to the administration  
         of angioplasty.
25.     The method of claim 20 wherein the implanting occurs during the administration  
10    of angioplasty.
26.     The method of claim 20 wherein the implanting occurs after the administration of  
         angioplasty.
27.     A kit comprising the stent of claim 1 and directions for its use.